The aim of this study was to evaluate whole-body molecular imaging response assessment for [177Lu]Lu-PSMA-617 RLT, based on the determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT. The gene discussed is FOLH1; the disease is neoplasm.